These results agree with the findings of other researchers who have shown that drug-resistant cancer cells have increased levels of TG2, which enhances NF-κB activity, in turn, through a novel mechanism, namely the formation of a TG2- NF-κB complex [13,15,20,43]. The gene discussed is NFKB1; the disease is cancer.